AI PROTEINS

Serial Number 97386010
Registration 7281401
700

Registration Progress

Application Filed
Apr 28, 2022
Under Examination
Approved for Publication
Published for Opposition
Registered
Jan 16, 2024

Trademark Image

AI PROTEINS

Basic Information

Serial Number
97386010
Registration Number
7281401
Filing Date
April 28, 2022
Registration Date
January 16, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Jan 16, 2024
Registration
Registered
Classes
042

Rights Holder

AI Proteins, Inc.

03
Address
4 Corporate Drive, Suite 100
Andover, MA 01810

Ownership History

AI Proteins, Inc.

Original Applicant
03
Andover, MA

AI Proteins, Inc.

Original Registrant
03
Andover, MA

Legal Representation

Attorney
Duan Wu

Application History

13 events
Date Code Type Description Documents
Jan 22, 2024 NRCS E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Jan 16, 2024 NRCS E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Jan 16, 2024 R.SR A REGISTERED-SUPPLEMENTAL REGISTER Loading...
Aug 26, 2023 CNTA O APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER Loading...
Jun 2, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jun 1, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jun 1, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Mar 9, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Mar 9, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
Mar 9, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Feb 15, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
May 3, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 2, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Custom design, engineering, research, development and testing services in the field of peptide materials, polypeptide and miniprotein synthesis, protein and miniprotein uses for medical, scientific, agricultural, industrial and technological applications; Pharmaceutical research and development; Application service provider (ASP) featuring software using artificial intelligence for designing protein and miniprotein pharmaceuticals; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Consulting services in the field of pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases, autoimmune diseases, infectious diseases, metabolic disorders, cognitive disorders, heart diseases, kidney diseases, neurological diseases, pain, inflammation and cancer; Software as a service (SAAS) services featuring software using artificial intelligence for designing protein and miniprotein pharmaceuticals; and Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines
First Use Anywhere: Dec 9, 2021
First Use in Commerce: Dec 9, 2021

Classification

International Classes
042